Revolution Medicines clinical trials we track

Check company identity source

Phase 3 7 trials

TrialDrugs studiedStatusPrimary completion
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCNCT07777822pembrolizumab, pemetrexed + cisplatin /carboplatin, zoldonrasibRecruiting2029-10Estimated
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232daraxonrasibRecruiting2029-05-10Estimated
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaNCT07805954daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasibRecruiting2029-03Estimated
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT076217185-Fluorouracil, Gemcitabine (GEM), Irinotecan, Leucovorin (Calcium Folinate) and 3 moreRecruiting2028-12-30Estimated
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445daraxonrasib, gemcitabine, nab-paclitaxelRecruiting2028-04Estimated
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784daraxonrasib, docetaxelRecruiting2027-12-01Estimated
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT066253205-fluorouracil, Gemcitabine, Irinotecan, Liposomal irinotecan and 4 moreActive not recruiting2026-06Estimated

Phase 2 1 trial

Phase 1 / 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival (PFS) Description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years. After: Measure: Progression free survival (PFS) as assessed by blinded independent central review (BICR) Description: Comparison of PFS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR. Time frame: Up to approximately 2 years Measure: Overall survival (OS) Description: Comparison of OS of daraxonrasib + gemcitabine and nab-paclitaxel (Arm B) versus gemcitabine and nab-paclitaxel (Arm C). OS is defined as the time from randomization until death from any cause. Time frame: Up to approximately 2 years.

Primary completion date changed

Before: Jun 2028. After: Apr 2028.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population. After: Measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population.

Planned enrollment increased by 170 participants

Before: 420 participants (planned). After: 590 participants (planned).

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 460 participants (planned). After: 501 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source